SynthesisRheumatology international2023
A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19.
Synthesis in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Vaccination in systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026Review
- Review
- Post-COVID-19 Thyroid Function Changes in Primary Care: A Retrospective Observational Study.Healthcare (Basel, Switzerland) · 2026Article
- COVID-19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans.Arthritis care & research · 2026Article
- Autoimmune manifestations recorded after SARS-CoV-2 vaccination.Clinical and experimental vaccine research · 2025Article
- Review
- Rising incidence of systemic autoimmune inflammatory rheumatic diseases during the COVID-19 pandemic: a geographical cohort study.RMD open · 2025Article
- Ethnic heterogeneity of juvenile arthritis in the Republic of Sakha (Yakutia) related to a high human leukocyte antigen B27 frequency.World journal of clinical pediatrics · 2025Article
- Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.Journal of clinical medicine · 2025Review
- Article
- From infection to autoimmunity: can COVID-19 spark new auto-immune conditions?Respiratory medicine case reports · 2025Article
- SARS-CoV-2 ORF8 drives osteoclastogenesis in preexisting immune-mediated inflammatory diseases.JCI insight · 2024Article
- Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.Rheumatology international · 2024Review
- RNAseq-based transcriptomics of treatment-naïve multi-inflammatory syndrome in children (MIS-C) demonstrates predominant activation of matrisome, innate and humoral immune pathways.Rheumatology international · 2024Article
- Anasarca and spontaneous intramuscular haemmorhage in a dermatomyositis patient: case report and review of the literature.Clinical rheumatology · 2024Review
- Interplay between Comorbidities and Long COVID: Challenges and Multidisciplinary Approaches.Biomolecules · 2024Review
- Incidence, management and prognosis of new-onset sarcoidosis post COVID-19 infection.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- The relationship between infectious agents and juvenile dermatomyositis: a narrative update from the pediatric perspective.Frontiers in immunology · 2024Review
- Prevalence, incidence, and mortality of Raynaud's phenomenon, Sjögren's syndrome and scleroderma: an umbrella review of systematic reviews.Rheumatology advances in practice · 2024Review
- Is Pulmonary Involvement a Distinct Phenotype of Post-COVID-19?Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The "population" was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and "intervention" as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1 years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7 days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died-one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.